Elevated expression of CXCL16 correlates with poor prognosis in patients with colorectal cancer

Figures & data

Table 1 Correlations between CXCL16 expression and clinicopathological features

Characteristics	Number	CXCL16 negative (N=66)	CXCL16 positive (N=76)	Χ^2 value	P-value
Gender
Male	86	39	47
Female	56	27	29	0.112	0.738
Age
＜60 years	63	27	36
≥60 years	79	39	40	0.597	0.440
Tumor size
＜5 cm	71	39	32
≥5 cm	71	27	44	4.077	0.043
Differentiation degree
Moderate to well	109	56	53
Poor	33	10	23	4.522	0.046
Tumor location
Right colon	36	15	21
Left colon	106	51	55	0.449	0.503
T stage
1	2	1	1
2	21	13	8
3	109	47	62
4	10	5	5	2.563	0.464
N stage
0	86	46	40
1	37	15	22
2	19	5	14	5.328	0.070
M stage
0	122	61	61
1	20	5	15	4.317	0.038
TNM stage
Ⅰ	13	9	4
Ⅱ	66	34	32
Ⅲ	43	18	25
IV	20	5	15	7.456	0.059
Chemotherapy regimen
No	29	16	13
Capecitabine	9	3	6
CapeOX	72	34	38
mFOLFOX6	26	9	17
Other*	6	4	2	3.976	0.409

Note: *Including FOLFIRI, bevacizumab and cetuximab.

Figure 1 Immunohistochemical staining of CXCL16 expression in CRC.

Table 2 Cox proportional hazard regression analysis for overall survival (OS)

	Univariate analysis			Multivariate analysis
Characteristics	HR	95% CI	P	HR	95% CI	P
CXCL16
Negative
Positive	2.422	1.390–4.220	0.002	2.026	1.128–3.640	0.018
Gender
Male
Female	1.416	0.837–2.395	0.194
Age
＜60 years
≥60 years	0.683	0.404–1.154	0.155
Tumor Size
＜5 cm
≥5 cm	1.877	1.097–3.211	0.022	1.262	0.676–2.359	0.465
Differentiation degree
Moderate to well
Poor	2.614	1.508–4.530	0.001	1.969	1.016–3.817	0.045
Tumor location
Right colon
Left colon	1.495	0.773–2.890	0.232
T stage
1
2
3
4	2.052	1.190–3.540	0.010	1.786	1.016–3.139	0.044
N stage
0
1
2	1.736	1.257–2.397	0.001	1.481	1.027–2.135	0.035
M stage
0
1	5.455	3.025–9.837	＜0.001	3.532	1.801–6.927	＜0.001
Chemotherapy regimen
No
Capecitabine
CapeOX
mFOLFOX6
Other*	1.267	0.987–1.625	0.063

Note: *Including FOLFIRI, bevacizumab, and cetuximab.

Figure 2 The 5-year overall survival rates of CXCL16-positive patients were significantly lower than those of CXCL16-negative patients (P=0.002).

Figure 3 The 5-year overall survival rates were not significantly different between CXCL16-positive and CXCL16-negative patients with stage I/II CRC (P=0.181).

Figure 4 The 5-year overall survival rates of CXCL16-positive patients were significantly lower than those of CXCL16-negative patients with stage III/IV CRC (P=0.011).